225.40
+2.68%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hikal
Its shares trade on NSE under the ticker HIKAL.NS. It has been listed since 8 July 1988. In the fiscal year to 31 March 2025, it reported revenue of ₹18.60bn and net income of ₹908.0m. At that date it held total assets of ₹25.29bn and shareholders' equity of ₹12.62bn.
Hikal Ltd. engages in the manufacture of chemical intermediates, specialty chemicals, active pharma ingredients, and contract research activities. The company is headquartered in Navi Mumbai, Maharashtra. The firm operates through two segments: pharmaceuticals and crop protection. The Pharmaceuticals segment produces active pharmaceutical ingredients. Its facilities are in Jigani, Bangalore and Panoli, Gujrat. The Crop protection segment produces pesticides and herbicides. Its facilities are in Taloja, Mahad, Maharashtra and Panoli, Gujarat. The Company’s products and services include gabapentin; thiabendazole, and diuron contract development and custom manufacturing of intermediates; application programming interface (APIs); and artificial intelligence (AI’s). The firm supplies its products to customers across the globe in the United States, Japan, Europe, Canada, Southeast Asia, Latin American, India and RoW.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 8 Jul 1988
- Employees
- 2,142
- Website
- hikal.com ↗
Leadership
Pay as last reported
- Mr. Jai HiremathExecutive Chairman of the Board, since 2022₹52.8m
- Mr. Sameer HiremathChief Executive Officer, Managing Director, Executive Director, since 2003₹47.9m
- Mr. Kuldeep JainChief Financial Officer₹12.5m
- Mr. Rajasekhar ReddyCompliance Officer, Company Secretary₹8.3m
- Mr. Sarangan SureshAdditional Executive Director, since 2024
- Mrs. Sugandha HiremathNon-Executive Director₹2.0m
- Mr. Amit KalyaniNon-Executive Director₹1.3m
- Mr. Shrikrishna AdivarekarIndependent Non-Executive Director₹1.5m
- Mr. Berjis DesaiNon-Executive Independent Director₹500,000
- Mr. Ravi KapoorAdditional Non-Executive Independent Director₹430,000
- Ms. Shivani SachdevaIndependent Non-Executive Director₹1.9m
- Ms. Ranjana SalgaocarAdditional Non-Executive Independent Director₹110,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 93
- Social
- 68
- Governance
- 35
- Direct emissions (scope 1)
- 21,410.71 t
- Energy emissions (scope 2)
- 67,287.01 t
- Women in the workforce
- 6%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hikal Ltd. manufactures active pharmaceutical ingredients in Jigani, Bangalore and Panoli, Gujarat.
- Hikal Ltd. produces pesticides and herbicides in Taloja, Mahad, Maharashtra and Panoli, Gujarat.
- Hikal Ltd. supplies products globally to the United States, Japan, Europe, Canada, Southeast Asia, Latin America, India, and RoW.
Weaknesses
- Hikal Ltd. operates in the Pharmaceuticals sector with 2,142 employees.
- Hikal Ltd. has facilities in Jigani, Bangalore and Panoli, Gujarat for pharmaceuticals.
- Hikal Ltd. has facilities in Taloja, Mahad, Maharashtra and Panoli, Gujarat for crop protection.
Opportunities
- Hikal Ltd. offers contract development and custom manufacturing of intermediates for global markets.
- Hikal Ltd. provides artificial intelligence (AI) applications in pharmaceuticals and crop protection.
- Hikal Ltd. develops APIs (application programming interfaces) for active pharmaceutical ingredients.
Threats
- Hikal Ltd. faces competition in the global pharmaceutical market.
- Hikal Ltd. operates in the Health Care sector with a focus on crop protection.
- Hikal Ltd. relies on facilities in Panoli, Gujarat for both pharmaceuticals and crop protection.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.